MARKET

ICCC

ICCC

ImmuCell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.08
-0.27
-2.89%
Closed 16:00 03/05 EST
OPEN
9.50
PREV CLOSE
9.35
HIGH
10.03
LOW
8.70
VOLUME
61.98K
TURNOVER
--
52 WEEK HIGH
13.20
52 WEEK LOW
3.700
MARKET CAP
65.49M
P/E (TTM)
-64.0790
1D
5D
1M
3M
1Y
5Y
DJ ImmuCell Corporation CEO Michael Brigham on Q4 2020 Results -- Earnings Call Transcript >ICCC
Dow Jones · 02/23 15:19
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
ImmuCell Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / ImmuCell Corp. (NASDAQ:ICCC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 9:00 AM Eastern Time.
ACCESSWIRE · 02/23 12:15
BRIEF-ImmuCell Makes Important Regulatory Submission
reuters.com · 02/22 22:36
ImmuCell Q4 EPS $0.03 Up From $(0.04) YoY, Sales $3.74M Miss $4.00M Estimate
ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.03 per share. This is a 175 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $3.74
Benzinga · 02/22 21:09
Immucell 4Q Product Sales $3.7M>ICCC
Immucell 4Q Product Sales $3.7M>ICCC
Dow Jones · 02/22 21:07
Immucell 4Q EPS 3c >ICCC
Immucell 4Q EPS 3c >ICCC
Dow Jones · 02/22 21:07
ImmuCell EPS beats by $0.10, beats on revenue
ImmuCell (ICCC): FY GAAP EPS of -$0.14 beats by $0.10.Revenue of $15.3M beats by $0.16M.Press Release
Seekingalpha · 02/22 21:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICCC. Analyze the recent business situations of ImmuCell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.14M
% Owned: 15.83%
Shares Outstanding: 7.21M
TypeInstitutionsShares
Increased
5
18.61K
New
6
5.18K
Decreased
3
5.16K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
David Tomsche
President/Chief Executive Officer/Treasurer/Secretary/Director
Michael Brigham
Chief Scientific Officer/Vice President
Joseph Crabb
Vice President/Director of Sales/Director of Marketing/Director
Bobbi Brockmann
Vice President
Elizabeth Williams
Independent Director
David Cunningham
Independent Director
Steven Rosgen
Independent Director
Jonathan Rothschild
Independent Director
Paul Wainman
No Data
About ICCC
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.